Blurbs

BioNTech SE (BNTX) Receives a Hold from UBS

In a report released yesterday, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTXResearch Report), with a price target of $168.00. The company’s shares closed last Wednesday at $141.98, close to its 52-week low of $117.08.

According to TipRanks.com, Merle is ranked #6814 out of 7904 analysts.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioNTech SE with a $236.70 average price target, implying a 69.5% upside from current levels. In a report issued on June 15, Goldman Sachs also maintained a Hold rating on the stock with a $206.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on BioNTech SE’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.37 billion and net profit of $3.7 billion. In comparison, last year the company earned revenue of $2.05 billion and had a net profit of $1.13 billion.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.

Read More on BNTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed